This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Canada's Competition Bureau not challenging GSK, Novartis deal in light of US FTC settlement

( February 23, 2015, 17:15 GMT | Official Statement) -- MLex Summary: Canada's Competition Bureau has said that it does not currently intend to challenge a major three-part transaction between GlaxoSmithKline and Novartis that pertains to their consumer healthcare, vaccine and oncology businesses. An agreement between the US Federal Trade Commission and Novartis that requires the sale of some assets to Array BioPharma has satisfied bureau concerns about potentially reduced competition. The bureau issued a so-called no action letter, it said. Full statement follows below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login